The committee noted that the evidence presented for Thopaz+ was mainly for its use in patients after pulmonary resection. The clinical experts confirmed that this reflected their experience in the NHS ...

The EAC considered that of the 6 randomised controlled trials: Pompili et al. (2014) was well designed and reported, and of excellent quality 4 were of good quality with clear protocols and results ...